Imperfectness of today’s methods for conducting meta-analyses in systematic reviews and health technology assessments (HTAs) that are more and more frequently used as a basis for reimbursement decisions, could result in even denial of public financing for a drug or other treatment that is actually worth financing. The credibility of results of meta-analyses could be increased by applying methods a ...